Epcoritamab
Small Lymphocytic Lymphoma
City of Hope Medical Centermonoclonal_antibodyPhase 2Active
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 89/ 100
Competitive context
8 Active assets in the Small Lymphocytic Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PREDNISONE TABLETS AstraZeneca | Phase 3 | BBB |
(+)-VINCRISTINE AstraZeneca | Phase 3 | BB |
Eloxatin City of Hope Medical Center | Phase 2 | BB |
PCV 13 Massachusetts General Hospital | Phase 2 | B |
Imexon University of Rochester | Phase 2 | B |
View all 18 →
Same molecule, other indications
Epcoritamab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →